Healthcare Equipment and Supplies
Company Overview of Sebacia, Inc.
Sebacia, Inc., a medical device company, focuses on creating light-based therapies for the treatment of dermatological conditions. It is developing a device for the treatment of acne. Sebacia, Inc. was formerly known as TIF Acquisition XII, Inc. The company was incorporated in 2008 and is based in Duluth, Georgia.
2905 Premiere Parkway
Duluth, GA 30097
Founded in 2008
Key Executives for Sebacia, Inc.
Chief Executive Officer, President and Director
Vice President of Engineering and Program Management
Compensation as of Fiscal Year 2015.
Sebacia, Inc. Key Developments
Sebacia, Inc. Hires Pedro Medrano as Vice President, Engineering and Program Management
Jun 25 15
Sebacia, Inc. hired Pedro Medrano as Vice President, Engineering and Program Management. In his new role, Mr. Medrano will lead commercialization readiness for Sebacia Treatment, a potential new in-office procedure for acne, one of the most common dermatological conditions. The Sebacia Treatment utilizes hair removal lasers, already in routine use among dermatologists, in combination with proprietary Sebacia Gold Microparticles, and is designed to deliver lasting results from a few, simple treatments performed at a dermatologist's office. Prior to joining Sebacia, Mr. Medrano was Director of the Project Management Office for Philips' Nuclear Medicine and Imaging business, responsible for new product development and sustaining programs.
Sebacia, Inc. Announces Positive Results of Two Independent Clinical Studies in Acne
Jan 28 15
Sebacia, Inc. announced the presentation of positive clinical results from two independent studies conducted in Europe investigating the use of Sebacia gold microparticles to treat acne. The microparticles are proprietarily designed to be used with an approved dermatology laser to reduce the size and activity of sebaceous glands and follicles, which are responsible for acne. The two studies evaluated Sebashell treatment in a total of 97 people with acne. The studies were designed as 1:1 randomization with crossover control groups. The control arm in the first study was over-the-counter face wash and in the second study was the suspension without Sebacia microparticles and laser treatment. Results showed significant reduction in inflammatory lesions and IGA scores in the treated arm versus the control arms at 12 weeks post baseline in both studies. Inflammatory lesion count reduction was approximately 60% at six months post baseline, indicating robust durability. Treatment was well tolerated, and side effects were limited to transient mild erythema (redness) and mild edema (swelling).
Similar Private Companies By Industry
Recent Private Companies Transactions
May 21, 2015
Most Searched Private Companies
Sponsored Financial Commentaries